Response to chemotherapy of solitary fibrous tumour: A retrospective study

European Journal of Cancer

Volumn 49, Issue 10, 2013, Pages 2376-2383

  Stacchiotti, S ^a   Libertini, M ^a   Negri, T ^a   Palassini, E ^a   Gronchi, A ^a   Fatigoni, S ^b   Poletti, P ^c   Vincenzi, B ^d   Dei Tos, A P ^e   Mariani, L ^a   Pilotti, S ^a   Casali, P G ^a  

^a NATIONAL CANCER INSTITUTE   (Italy)

^b S MARIA HOSPITAL   (Italy)

^c OSPEDALI RIUNITI   (Italy)

^d UNIVERSITY CAMPUS BIO MEDICO   (Italy)

^e General Hospital of Treviso   (Italy)

Author keywords

Anthracycline; Chemotherapy; Doxorubicin; Haemangioperycitoma; Ifosfamide; Sarcoma; Solitary fibrous tumour

Indexed keywords

DACARBAZINE; DEXAMETHASONE; DOXORUBICIN; EPIRUBICIN; GRANULOCYTE COLONY STIMULATING FACTOR; IFOSFAMIDE; MESNA; ONDANSETRON;

ADULT; ADVANCED CANCER; AGE DISTRIBUTION; AGED; CANCER CLASSIFICATION; CANCER COMBINATION CHEMOTHERAPY; CANCER GROWTH; CANCER LOCALIZATION; CELL DEDIFFERENTIATION; CLINICAL ARTICLE; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED STUDY; DEDIFFERENTIATED SOLITARY FIBROUS TUMOR; DRUG MEGADOSE; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOPHENOTYPING; MALE; MALIGNANT SOLITARY FIBROUS TUMOR; METASTASIS; MONOTHERAPY; NUCLEAR MAGNETIC RESONANCE IMAGING; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RETROSPECTIVE STUDY; REVIEW; SOLITARY FIBROUS TUMOR; SURVIVAL TIME; TREATMENT DURATION; TREATMENT RESPONSE; WORLD HEALTH ORGANIZATION;

EID: 84878394995     PISSN: 09598049     EISSN: 18790852     Source Type: Journal    
DOI: 10.1016/j.ejca.2013.03.017     Document Type: Article

References (30)

1. C.A. Stiller, A. Trama, and D. Serraino Descriptive epidemiology of sarcomas in Europe: report from the RARECARE project Eur J Cancer 49 2013 684 695
2. J.K.C. Chan Solitary fibrous tumor: everywhere, and a diagnosis in vogue Histopathology 31 1997 568 576
3. C.D.M. Fletcher, K.K. Unni, and F. Mertens Tumours of Soft tissue and Bone. Pathology and genetics. World Health Organization classification of tumours 2002 IARC Press Lyon
4. D.N. Louis, H. Ohgaki, and O.D. Wiestler WHO classification of tumours of the central nervous system World Health Organization classification of tumours 4th ed. 2007 International Agency for Research on Cancer Lyon
5. P. Collini, T. Negri, and M. Barisella High-grade sarcomatous overgrowth in solitary fibrous tumor: a clinico-pathological study of 10 cases Am J Surg Pathol 36 2012 1202 1215
6. J.M. Mosquera, and C.D.M. Fletcher Expanding the spectrum of malignant progression solitary fibrous tumor - a study of 8 cases with a discrete anaplastic component - is this dedifferentiated SFT? Am J Surg Pathol 33 2009 1314 1321
7. G. Magro, C. Emmanuele, and M. Lopes Solitary fibrous tumour of the kidney with sarcomatous overgrowth. Case report and review of the literature APMIS 116 2008 1020 1025
8. P.P. Wong, and A. Yagda Chemotherapy of malignant hemangiopericytoma Cancer 41 1978 1256 1260
9. E. Galanis, J.C. Buckner, and B.W. Scheithauer Management of recurrent meningeal hemangiopericytoma Cancer 82 1998 1915 1920
10. G.F. Beadle, and B.L. Hillcoat Treatment of advanced malignant hemangiopericytoma with combination adriamycin and DTIC: a report of four cases J Surg Oncol 22 1983 167 170
11. M.S. Park, S. Patel, and V. Ravi The role of chemotherapy in advanced hemangiopericytoma/solitary fibrous tumor J Clin Oncol 29 2011 supplement, abstract 10097
12. L. Chaigneau, E. Kalbacher, and A. Thiery-Vuillemin Efficacy of trabectedin in metastatic solitary fibrous tumor Rare Tumors 2011 10.4081/rt.2011.e29
13. J. Martinez-Trufero, J. Alfaro, and F. Felipo Response to trabectedin treatment in a highly pretreated patient with an advanced meningeal hemangiopericytoma Anticancer Drugs 21 2010 795 798
14. M.S. Park, S.R. Patel, and J.A. Ludwig Activity of temozolomide and bevacizumab in the treatment of locally advanced, recurrent, and metastatic hemangiopericytoma and malignant solitary fibrous tumor Cancer 117 2011 4939 4947
15. K. Mulamalla, A.M. Truskinovsky, and A.Z. Dudek Rare case of hemangiopericytoma responds to sunitinib Transl Res 151 2008 129 133
16. S. George, P. Merriam, and R.G. Maki Multicenter phase II trial of sunitinib in the treatment of non-gastrointestinal stromal tumor sarcomas J Clin Oncol 27 2009 3154 3160
17. J. Domont, C. Massard, and N. Lassau Hemangiopericytoma and antiangiogenic therapy: clinical benefit of antiangiogenic therapy (sorafenib and sunitinib) in relapsed malignant haemangioperictoma/solitary fibrous tumour Invest New Drugs 28 2010 199 202
18. S. Stacchiotti, T. Negri, and E. Palassini Sunitinib malate and figitumumab in solitary fibrous tumor: patterns and molecular bases of tumor response Mol Cancer Ther 9 2010 1286 1297
19. S. Stacchiotti, T. Negri, and M. Libertini Sunitinib in solitary fibrous tumor Ann Oncol 23 2012 3171 3179
20. S. Sleijfer, I. Ray-Coquard, and Z. Papai Pazopanib, a multikinase angiogenesis inhibitor, in patients with relapsed or refractory advanced soft tissue sarcoma: a phase II study from the European organisation for research and treatment of cancer-soft tissue and bone sarcoma group (EORTC study 62043) J Clin Oncol 27 2009 3126 3132
21. R. Quek, Q. Wang, and J.A. Morgan Combination mTOR and IGF-1R inhibition: phase I trial of everolimus and figitumumab in patients with advanced sarcomas and other solid tumors Clin Cancer Res 17 2011 871 879
22. P. Therasse, S.G. Arbuck, and E.A. Eisenhauer New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer Institute of the United States, National Cancer Institute of Canada J Natl Cancer Inst 92 2000 205 206
23. W.E. Kaplan, and P. Meier Nonparametric estimation from incomplete observations J Am Stat Assoc 53 1958 457 481
24. M.C. Chamberlain, and M.J. Glantz Sequential salvage chemotherapy for recurrent intracranial hemangiopericytoma Neurosurgery 63 2008 720 726
25. A.C. Hsieh, and D. Ruggero Targeting eukaryotic translation initiation factor 4E (eIF4E) in cancer Clin Cancer Res 16 2010 4914 4920
26. B. Culjkovic, I. Topisirovic, and K.L. Borden Controlling gene expression through RNA regulons: the role of the eukaryotic translation initiation factor eIF4E Cell Cycle 6 2007 65 69
27. B. Culjkovic, K. Tan, and S. Orolicki The eIF4E RNA regulon promotes the Akt signaling pathway J Cell Biol 181 2008 51 63
28. G.H. Williams, and K. Stoeber The cell cycle and cancer J Pathol 226 2012 352 364
29. F. Bertucci, P. Finetti, R. Sabatier, and D. Birnbaum The CINSARC signature: prognostic and predictive of response to chemotherapy? Cell Cycle 9 2010 4025 4027
30. M. Loddo, S.R. Kingsbury, and M. Rashid Cell-cycle-phase progression analysis identifies unique phenotypes of major prognostic and predictive significance in breast cancer Br J Cancer 100 2009 959 970